U.S. markets closed
  • S&P 500

    3,363.00
    +27.53 (+0.83%)
     
  • Dow 30

    27,781.70
    +329.04 (+1.20%)
     
  • Nasdaq

    11,167.51
    +82.26 (+0.74%)
     
  • Russell 2000

    1,507.69
    +2.96 (+0.20%)
     
  • Crude Oil

    39.86
    +0.57 (+1.45%)
     
  • Gold

    1,890.90
    -12.30 (-0.65%)
     
  • Silver

    23.34
    -1.10 (-4.52%)
     
  • EUR/USD

    1.1721
    -0.0025 (-0.21%)
     
  • 10-Yr Bond

    0.6770
    +0.0320 (+4.96%)
     
  • GBP/USD

    1.2925
    +0.0065 (+0.51%)
     
  • USD/JPY

    105.4600
    -0.1950 (-0.18%)
     
  • BTC-USD

    10,731.13
    -113.08 (-1.04%)
     
  • CMC Crypto 200

    221.30
    -0.09 (-0.04%)
     
  • FTSE 100

    5,866.10
    -31.40 (-0.53%)
     
  • Nikkei 225

    23,185.12
    -353.98 (-1.50%)
     

Inari Medical to Present at the Canaccord Genuity 40th Annual Growth Conference

Inari Medical, Inc.

IRVINE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced the company will be participating in the upcoming Canaccord Genuity 40th Annual Virtual Growth Conference.

Inari’s management is scheduled to present on Wednesday, August 12 at 4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.

Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.

Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com